Global Parkinson’s disease Therapeutics Market Anticipated to Surge Expressively at a CAGR of 10.9% during 2017 – 2025

The profile of Parkinson's disease has certainly risen in recent years, and this tends to be a very frightening disease to be diagnosed with. According to a latest study findings, the global Parkinson’s disease therapeutics market is witnessing a relatively high growth owing to rise in awareness regarding Parkinson’s disease, rapidly growing geriatric population, promising pipeline drugs, and new product launches. Which provide wide-ranging insights into the market current scenario and future growth prospects during the mentioned forecast period of 2017-2025.

Snapshot and Forecast Predictions

Parkinson's disease is a condition in which parts of the brain become progressively damaged over many years. It primarily causes tremors, muscle stiffness, improper motor movements, and gait and balance problems. The exact cause of the disease is still unknown, which is why the therapeutic area has become more active for this disease. It is estimated that worldwide around 7 to 10 million people are affected by disease and every year around 60,000 Americans are diagnosed with it. Rise in incidence rates of Parkinson’s disease in developed countries are motivating the growth of the global market. According to the study prime findings, the global Parkinson’s disease therapeutics market is projected to witness CAGR of more than 10.9% from 2017 to 2025, and to exceed the US$ 5.24 Bn by 2025. In 2016, the market was valued at US$ 2.18 Bn.

Also Read-Top Essential Oils For Broken Bones

The market overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the Parkinson’s disease therapeutics market and is likely to influence the market in the near future. In this study, market attractiveness analysis has been also provided in the market overview section in order to explain the intensity of competition in the market across different geographies. Regions highlighted in the study includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. From a geographical standpoint, the research observes that Europe is a highly attractive market and is expected to expand at a significant CAGR during the forecast period.

Moreover, the global Parkinson’s disease therapeutics market can be divided into four segments based on drug class, route of administration, and distribution channel. By drug class, the study levodopa combination therapy, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and others. Of these, levodopa combination therapy is considered as a highly effective treatment for monitoring the motor symptoms throughout the stages of Parkinson’s disease. By route of administration, the study highlights oral, transdermal, subcutaneous, intestinal infusion, and others.

Competitive Tracking

Another vital section of the report is competitive landscape featuring some of the top companies in Parkinson’s disease therapeutics market. They include AbbVie Inc., Novartis AG, F. Teva Pharmaceutical Industries Ltd., Hoffmann-La Roche AG, and UCB Inc, which exhibit the widest geographical outreach.

Also Read-How to Move WhatsApp Messages to a New Phone